Search

Your search keyword '"Felker, G"' showing total 2,286 results

Search Constraints

Start Over You searched for: Author "Felker, G" Remove constraint Author: "Felker, G"
2,286 results on '"Felker, G"'

Search Results

252. Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction

254. Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study

260. Phase III clinical trial end points in acute heart failure syndromes: A virtual roundtable with the acute heart failure syndromes international working group

261. Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.

262. Characteristics and clinical outcomes of patients with acute heart failure with a supranormal left ventricular ejection fraction.

271. Improvements in Signs and Symptoms During Hospitalization for Acute Heart Failure Follow Different Patterns and Depend on the Measurement Scales Used: An International, Prospective Registry to Evaluate the Evolution of Measures of Disease Severity in Acute Heart Failure (MEASURE-AHF)

281. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure

282. Additional file 1 of Circulating long chain acylcarnitines and outcomes in diabetic heart failure: an HF-ACTION clinical trial substudy

283. Additional file 2 of Circulating long chain acylcarnitines and outcomes in diabetic heart failure: an HF-ACTION clinical trial substudy

284. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

285. Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction

286. Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF

287. Intercountry Differences in Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure

289. Growth differentiation factor‐15, treatment with liraglutide, and clinical outcomes among patients with heart failure

290. Association Between Angiotensin Receptor–Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction

291. Interleukin-6 and Outcomes in Acute Heart Failure: An ASCEND-HF Substudy

292. Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.

293. Differences in NT‐proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction

295. Heart Failure Strategically Focused Research Network: Summary of Results and Future Directions.

296. Splanchnic nerve modulation in heart failure: mechanistic overview, initial clinical experience, and safety considerations

297. The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure ( COSMIC ‐ HF )

298. Discordance between patient-predicted and model-predicted life expectancy among ambulatory patients with heart failure

299. Conduct of clinical trials in the era of COVID-19: JACC scientific expert panel

300. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Catalog

Books, media, physical & digital resources